Comparison of 2 Diffractive Trifocal IOLs
Launched by PRIM. PROF. DR. OLIVER FINDL, MBA · Nov 19, 2018
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
Spectacle independence is a central aim in modern cataract surgery. Although bilateral monofocal IOL implantation, aiming for emmetropia or low myopia, leads to high levels of patient satisfaction in distance vision, spectacle dependence for reading and other near vision tasks is the usual result.
The option commonly used to achieve spectacle independence are multifocal intraocular lenses (IOLs). Multifocal IOLs either use a refractive or diffractive design or a combination of both or segmented asymmetric optics. The principal of the refractive design is based on changing the route of ligh...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age-related cataract
- • Scheduled for bilateral cataract extraction
- • Motivated to be less spectacle dependant
- • Age 21 and older
- • Corneal astigmatism ≤ 1.5 D (Keratometry, IOL Master 700)
- • written informed consent prior to recruitment
- Exclusion Criteria:
- • Pregnancy (pregnancy test will be taken pre-operatively in women of reproductive age)
- • Retinitis pigmentosa
- • Chronic uveitis
- • Amblyopia
- • Pupil decentration \> 1mm center shift
- • preceded retinal surgery
- • preceded Laser-in-situ-Keratomileusis (LASIK)
- • Any ophthalmic abnormality that could compromise visual function or the measurements
About Prim. Prof. Dr. Oliver Findl, Mba
Prim. Prof. Dr. Oliver Findl, MBA, is a distinguished clinical trial sponsor renowned for his expertise in ophthalmology and a strong commitment to advancing medical research. With a robust academic background and extensive clinical experience, he leads innovative studies aimed at improving patient outcomes and fostering breakthroughs in eye care. Dr. Findl combines his clinical acumen with a strategic approach to trial management, ensuring rigorous adherence to ethical standards and regulatory compliance. His dedication to collaboration and excellence positions him as a trusted partner in the development of transformative therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials